Molecular pathology of thyroid cancer: diagnostic and clinical implications
- PMID: 19041825
- PMCID: PMC2615540
- DOI: 10.1016/j.beem.2008.09.017
Molecular pathology of thyroid cancer: diagnostic and clinical implications
Abstract
There is now a reasonably good understanding of the key oncogenic events involved in the initiation and progression of thyroid cancer. Many of these are characteristic of certain tumor types, and their presence conveys diagnostic and prognostic information. It is not yet clear how this information will be applied to clinical practice. Based on preclinical evidence, mutations of genes encoding certain kinases may also predict response to specific tyrosine kinase inhibitors, although this has not yet been explored systematically in clinical trials.
Conflict of interest statement
CONFLICT OF INTEREST STATEMENT
The authors have no conflicts of interest to declare.
References
-
- Sobrinho-Simoes M, Maximo V, Rocha AS, Trovisco V, Castro P, Preto A, et al. Intragenic mutations in thyroid cancer. Endocrinol Metab Clin North Am. 2008 Jun;37(2):333–62. viii. - PubMed
-
- Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006 May 10;295(18):2164–7. - PubMed
-
- DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004. World Health Organization Classification of Tumours.
-
- Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci. 2002 Jun;963:116–21. 116–21. - PubMed
-
- Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD, et al. Characterization of a multicomponent receptor for GDNF. Nature. 1996 Jul 4;382(6586):80–3. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
